NASDAQ · ARAY
Healthcare · Medical - Devices
$0.28
Down-$0.00 (-1.61%)
Updated Aug 14, 2026, 9:25 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ARAY closed at $0.28 after 21 trading sessions, up 3.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.2848 | $0.30 | $0.2728 | $0.2755 | 897.02K |
| Aug 12, 2026 | $0.2808 | $0.3015 | $0.2731 | $0.28 | 1.04M |
| Aug 11, 2026 | $0.29 | $0.3048 | $0.2876 | $0.2897 | 537.99K |
| Aug 10, 2026 | $0.285 | $0.31 | $0.273 | $0.2924 | 1.06M |
| Aug 7, 2026 | $0.3062 | $0.3243 | $0.285 | $0.285 | 995.14K |
| Aug 6, 2026 | $0.2758 | $0.2956 | $0.2723 | $0.2827 | 447.63K |
| Aug 5, 2026 | $0.3157 | $0.3157 | $0.2732 | $0.2743 | 718.79K |
| Aug 4, 2026 | $0.28 | $0.3162 | $0.28 | $0.3112 | 1.75M |
| Aug 3, 2026 | $0.2667 | $0.285 | $0.2625 | $0.2698 | 637.34K |
| Jul 31, 2026 | $0.2663 | $0.288 | $0.2577 | $0.2681 | 1.9M |
| Jul 30, 2026 | $0.2482 | $0.30 | $0.2361 | $0.285 | 9.85M |
| Jul 29, 2026 | $0.2393 | $0.253 | $0.2309 | $0.2309 | 1.16M |
| Jul 28, 2026 | $0.22 | $0.2662 | $0.22 | $0.2434 | 2.35M |
| Jul 27, 2026 | $0.2428 | $0.2428 | $0.2233 | $0.225 | 599.61K |
| Jul 24, 2026 | $0.234 | $0.2423 | $0.2279 | $0.2384 | 780.14K |
| Jul 23, 2026 | $0.2415 | $0.2416 | $0.2325 | $0.2382 | 1.22M |
| Jul 22, 2026 | $0.2523 | $0.2532 | $0.2416 | $0.2416 | 716.9K |
| Jul 21, 2026 | $0.2528 | $0.2579 | $0.2461 | $0.2501 | 970.23K |
| Jul 20, 2026 | $0.2733 | $0.2733 | $0.2489 | $0.2502 | 723.77K |
| Jul 17, 2026 | $0.2683 | $0.2683 | $0.253 | $0.2593 | 314.08K |
| Jul 16, 2026 | $0.2755 | $0.2755 | $0.2549 | $0.2653 | 539.39K |
The latest Smart Investors Daily articles mentioning ARAY.
ARAY research
Company profile and research snapshot.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 12, 2026 | Jefferies | Hold | — |
| May 7, 2026 | BTIG | Neutral | — |
| Feb 5, 2026 | BTIG | Buy | — |
| Nov 6, 2025 | BTIG | Buy | — |
| Aug 14, 2025 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 5, 2026
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 19, 2026.
Yahoo · Jul 30, 2026
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S
Yahoo · Jul 30, 2026
Accuray (ARAY) said late Wednesday it has entered into definitive agreements with TCW Asset Manageme
Benzinga · Jul 8, 2026
BTIG suspends Neutral rating on Accuray (NASDAQ:ARAY).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ARAY.
